KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to $566.8 million.

  • Royalty Pharma's Shares Outstanding (Diluted Average) fell 4.86% to $566.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $566.8 million, marking a year-over-year decrease of 4.86%. This contributed to the annual value of $594.1 million for FY2024, which is 1.46% down from last year.
  • Per Royalty Pharma's latest filing, its Shares Outstanding (Diluted Average) stood at $566.8 million for Q3 2025, which was down 0.60% from $570.2 million recorded in Q2 2025.
  • Royalty Pharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $607.3 million during Q1 2023, with a 5-year trough of $414.8 million in Q4 2021.
  • For the 3-year period, Royalty Pharma's Shares Outstanding (Diluted Average) averaged around $592.8 million, with its median value being $597.2 million (2024).
  • In the last 5 years, Royalty Pharma's Shares Outstanding (Diluted Average) soared by 71.52% in 2021 and then fell by 4.86% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's Shares Outstanding (Diluted Average) stood at $414.8 million in 2021, then climbed by 5.59% to $438.0 million in 2022, then spiked by 37.66% to $602.9 million in 2023, then decreased by 1.46% to $594.1 million in 2024, then declined by 4.86% to $566.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $566.8 million in Q3 2025, compared to $570.2 million in Q2 2025 and $578.1 million in Q1 2025.